CD5 and neoplasm: A number of studies have reported the putative involvement of CD5 in the modulation of antitumor responses, this including the effective treatment with a non-depleting anti-CD5 (Lyt-1) monoclonal antibody (mAb) [14], and the adaptation of human CD5 expression levels in tumor infiltrating lymphocytes (TILs) [15, 16].